Skip to main content

Table 4 Baseline and the incidence of ARDS

From: Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study

Patients Characteristics O+P group O group P value
All patients n = 39 n = 43  
patients had already got ARDS before received NAIs n = 3 n = 7  
Study patients n = 36 n = 36  
  Age (years): mean (SD) 52.58(12.70) 59.31(13.85) 0.44
  No. of male (%) 24 24 1.00
  Time from symptom onset to NAIs administration (days):median(IQR) 7.00(4.25, 8.00) 6.00(4.00,8.00) 0.57
  Viral load(log10 /ul) at day 0: median(IQR) 4.07(3.00, 4.47) 3.58(2.89,4.47) 0.73
  APACHE II score: mean(SD) 19.17(8.28) 20.22(7.76) 0.58
  New ARDS developed patients (%) 28(77.78) 23(63.89) 0.30
  1. O oseltamivir monotherapy, O+P oseltamivir-peramivir combination therapy, IQR interquartile range, percentile 25 – percentile75